Additional Information

Description

Fluzone® 2025–2026 (Flu-110) is a quadrivalent inactivated influenza vaccine formulated to provide active immunization against four influenza virus strains—two A and two B lineages—recommended for the 2025–2026 influenza season. This vaccine is produced using egg-based technology and is indicated for individuals aged 6 months and older. The quadrivalent composition enhances protection by covering both B lineages that may circulate during the season. 

The vaccine is supplied in a 5 mL multi-dose vial, with each vial containing ten 0.5 mL doses. It is administered intramuscularly, typically into the deltoid muscle in adults and older children, or the anterolateral thigh in infants. Fluzone® does not contain a live virus and cannot cause influenza illness. The multi-dose format contains thimerosal as a preservative to maintain sterility after vial puncture. 

Common adverse effects include pain, swelling, and redness at the injection site, as well as headache, muscle aches, and fatigue. In rare cases, serious events such as hypersensitivity reactions and Guillain-Barré syndrome may occur. The vaccine should not be administered to individuals with a known severe allergic reaction to any of its components or to previous influenza vaccinations.